PTPN22 and congenital bilateral aplasia of vas deferens from CFTR mutation: In mice with aortic valve injury, S18 administration markedly alleviated aortic valve lesions.<h4>Conclusion</h4>PTPN22 plays an essential role in the progression of CAVD, and inhibition of PTPN22 with S18 is a novel option for the further development of potent anti-CAVD drugs.